CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 8 clinical trials at NIH that match your search criteria

Cancer by type/disease: Colorectal Cancer

Trial and Protocol Number Colorectal Cancer	Principal Investigator	Referral Contact
Phase II
A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux^®) in EGFR Expressing Metastatic Colorectal Cancer (CRC) NCI-06-C-0164	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
No Phase
Outcomes in Education and Counseling for HNPCC Testing NCI-95-HG-0165	Don Hadley 301-496-3980 1-866-585-7192 ext. 2 (Toll Free)

Trial and Protocol Number Liver Cancer	Principal Investigator	Referral Contact
Phase II
A Phase II Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration via Peripheral Hepatic Perfusion (PHP) for Unresectable Primary and Metastatic Cancers of the Liver NCI-04-C-0273	Marybeth S. Hughes 301-594-9341	Carole Webb 301-451-6940 Webbcc@mail.nih.gov

Trial and Protocol Number Solid Tumor	Principal Investigator	Referral Contact
Phase II
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors NCI-09-C-0138	Shivaani Kummar 301-435-5402	Janelle Bingham 301-435-2715 jbingham@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) Using Lymphodepleting Conditioning Followed by Infusion of Anti-CEA TCR-Gene Engineered Lymphocytes NCI-09-C-0047	Steven A. Rosenberg 1-866-820-4505 (Toll Free)	Linda Williams 1-866-820-4505 (Toll Free) ncisbirc@mail.nih.gov
Phase I
A Phase I, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Refractory Solid Tumors Associated With EphA2 Expression NCI-09-C-0168	Elise C. Kohn 301-402-2726	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
An Open-Label Phase I Study to Evaluate the Safety and Tolerability of a Vaccine Consisting of Whole, Heat-Killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing Carcinoma NCI-09-C-0101	James L. Gulley 301-435-2956	Laura D. Otten 301-451-1228 1-866-611-6310 (Toll Free) ottenl@mail.nih.gov
No Phase
The Natural History of Solid Organ Cancer Stem Cells NCI-09-C-0079	Itzhak Avital 301-402-0083	Melissa Walker 301-402-9537 walkerme@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.